All news

Alcon closes $550M Neurotech deal for Encelto

Alpha Vantage · GuruFocus · · AI-summarised by FinFlash

Alcon Inc. has completed its $550 million acquisition of Neurotech Pharmaceuticals, gaining control of Encelto, an encapsulated cell therapy for idiopathic Macular Telangiectasia Type 2 that is expected to receive approval in 2025. GuruFocus calls Alcon modestly undervalued by 23.2% with a GF Score of 74/100, though institutional interest is mixed.

Read original source

ALC company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.